Bortezomib

Bortezomib
Clinical data
Trade names	Velcade, others
Other names	PS-341
AHFS/Drugs.com	Monograph
MedlinePlus	a607007
License data	US DailyMed: Bortezomib;
Pregnancy; category	AU: C;
Routes of; administration	Subcutaneous, intravenous
ATC code	L01XG01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	83%
Metabolism	Liver, CYP extensively involved
Elimination half-life	9 to 15 hours
Identifiers
CAS Number	179324-69-7 ;
PubChem CID	387447;
IUPHAR/BPS	6391;
DrugBank	DB00188 ;
ChemSpider	343402 ;
UNII	69G8BD63PP;
KEGG	D03150;
ChEMBL	ChEMBL325041 ;
PDB ligand	BO2 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID3040980 ;
ECHA InfoCard	100.125.601
Chemical and physical data
Formula	C19H25BN4O4
Molar mass	384.24 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@H](C(=O)N[C@H](B(O)O)CC(C)C)Cc1ccccc1)c2nccnc2;
	InChI InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 ; Key:GXJABQQUPOEUTA-RDJZCZTQSA-N ;
	(verify)

Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.^[4] This includes multiple myeloma in those who have and have not previously received treatment.^[3] It is generally used together with other medications.^[3] It is given by injection.^[4]

Common side effects include nausea, diarrhea, tiredness, low platelets, fever, numbness, low white blood cells, shortness of breath, rash and abdominal pain.^[4] Other severe side effects include low blood pressure, tumour lysis syndrome, heart failure, and reversible posterior leukoencephalopathy syndrome.^[4]^[3] It is in the class of medications known as proteasome inhibitor.^[4] It works by inhibiting proteasomes, cellular complexes that break down proteins.^[3]

Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004.^[4]^[3] It is on the World Health Organization's List of Essential Medicines.^[5] It is available as a generic medication.^[6]

^ "Bortezomib Baxter (Baxter Healthcare Pty Ltd)". Therapeutic Goods Administration (TGA). 2 May 2024. Retrieved 5 October 2024.
^ "Boruzu- bortezomib injection". DailyMed. 27 September 2024. Retrieved 11 November 2024.
^ ^a ^b ^c ^d ^e ^f "Velcade EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.
^ ^a ^b ^c ^d ^e ^f "Bortezomib Monograph for Professionals". Drugs.com. Retrieved 13 October 2019.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[1] "Bortezomib Baxter (Baxter Healthcare Pty Ltd)". Therapeutic Goods Administration (TGA). 2 May 2024. Retrieved 5 October 2024.

[Boruzu_FDA_label-2] "Boruzu- bortezomib injection". DailyMed. 27 September 2024. Retrieved 11 November 2024.

[EMA2019-3] ^ ^a ^b ^c ^d ^e ^f "Velcade EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.

[AHFS2019-4] ^ ^a ^b ^c ^d ^e ^f "Bortezomib Monograph for Professionals". Drugs.com. Retrieved 13 October 2019.

[WHO21st-5] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[6] "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[1]

[2]

[3]

[4]

[5]

[6]